6.2 Pharmacotherapy of Osteomyelitis, Septic Arthritis, and PJI

Pharmacotherapy of Osteomyelitis, Septic Arthritis, and PJI

Bone and joint infections represent complex, morbid clinical syndromes that require coordinated surgical debridement, precise microbiological sampling, and targeted antimicrobial pharmacotherapy. Because bone and prosthetic hardware exhibit unique physiological barriers—including poor vascular perfusion in cortical sequestra and dense glycocalyx biofilm formation on implants—pharmacotherapy must be optimized for bone penetration, biofilm eradication, and patient safety.

---

Osteomyelitis: Pathogenesis and Classification

Osteomyelitis is classified according to the Waldvogel system (based on clinical mechanism and duration) and the Cierny-Mader staging system (based on anatomical site and host physiological status).

Waldvogel Classification Mechanisms

1. Hematogenous Osteomyelitis: Results from bacteremic seeding of bone tissue.
   • Pediatric: Predominantly involves the highly vascularized metaphysis of rapidly growing long bones (tibia, femur), commonly caused by Staphylococcus aureus or Streptococcus pyogenes.
   • Adult: Predominantly manifests as vertebral osteomyelitis / spondylodiscitis in patients $>50$ years of age. Typical organisms include S. aureus (MSSA/MRSA), Enterobacterales (associated with urinary tract sources), and Mycobacterium tuberculosis (Pott disease). Infection typically involves the richly vascular subchondral bone plate, spreading across the intervertebral disc to adjacent vertebral bodies.
2. Contiguous Focus Osteomyelitis with Normal Vascularity: Results from direct microbial inoculation secondary to open fractures, penetrating trauma, orthopedic surgery, or adjacent soft-tissue infection (e.g., decubitus ulcers). Often monomicrobial initially (S. aureus, Streptococcus spp.).
3. Contiguous Focus Osteomyelitis with Vascular Insufficiency: Most commonly encountered as Diabetic Foot Osteomyelitis (DFO). Characterized by peripheral arterial disease, sensory peripheral neuropathy, and repetitive microtrauma. Lesions are characteristically polymicrobial, involving mixtures of aerobic Gram-positive cocci (S. aureus, streptococci, enterococci), Gram-negative bacilli (Proteus, E. coli, Klebsiella, Pseudomonas aeruginosa), and obligate anaerobes (Peptostreptococcus, Bacteroides fragilis).

Pathophysiological Evolution: Sequestrum and Involucrum

Microbial Inoculation / Vascular Thrombosis
                   │
                   ▼
   Intraosseous Pressure Elevation & Ischemia
                   │
                   ▼
      Cortical Bone Necrosis (SEQUESTRUM)
     [Avascular dead bone; biofilm harbor;
       impervious to systemic antibiotics]
                   │
                   ▼
   Reactive Subperiosteal Bone Deposition (INVOLUCRUM)
     [Surrounds sequestrum; cloacae drain pus]

Systemic antimicrobials cannot penetrate avascular sequestra; definitive clinical cure requires surgical resection of necrotic cortical bone alongside targeted antimicrobial therapy.

---

Diagnostic Evaluation: Bone Biopsy vs. Superficial Swabs

The Gold Standard: Bone Biopsy

The diagnostic gold standard for osteomyelitis is a percutaneous bone biopsy (performed under fluoroscopic or CT guidance through uninvolved, healthy skin) or an intraoperative open bone biopsy. Bone specimens must be sent for both aerobic/anaerobic microbiological cultures and histopathological examination (confirming osteonecrosis, acute/chronic inflammatory infiltrate, and bacterial elements).

• Antimicrobial Washout: In clinically stable, non-septic patients, withhold antimicrobial therapy for 1 to 2 weeks prior to biopsy to optimize culture recovery and avoid sterile, non-diagnostic specimens.

The Hazard of Superficial Swabs and Sinus Tract Cultures

Imaging Modalities and Clinical Laboratory Biomarkers

• Probe-to-Bone (PTB) Test: In diabetic foot ulcers, palpation of hard, gritty bone using a sterile blunt metallic probe demonstrates high sensitivity (>85%) and specificity (>90%) for underlying osteomyelitis in high-prevalence settings.
• Plain Radiography: Initial study in all suspected cases. Early findings are subtle; cortical erosion, periosteal reaction, and osteolytic changes lag clinical infection by 10 to 14 days and require 30% to 50% demineralization of bone before becoming visible on X-ray.
• Magnetic Resonance Imaging (MRI): Modality of choice, boasting sensitivity $>90\%$ and specificity $80\%$ to $90\%$. Accurately delineates bone marrow edema (decreased T1 signal, increased T2/STIR signal), cortical erosion, periosteal elevation, and adjacent sinus tracts or soft-tissue abscesses.
• Inflammatory Biomarkers (ESR and CRP): Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are elevated in active osteomyelitis. CRP has a short half-life (~19 hours) and tracks rapid clinical improvement and debridement success. ESR normalizes slowly over weeks to months. An initial ESR $>70\text{ mm/h}$ or CRP $>20\text{ mg/L}$ strongly supports the diagnosis in compatible clinical settings.

---

Pharmacotherapy and Evidence-Based Durations of Therapy

Pathogen-Directed Antimicrobial Regimens

Duration of Therapy Stratified by Surgical Resection Margins

The required duration of antimicrobial therapy in osteomyelitis is dictated by the adequacy of surgical debridement and the histological status of the remaining bone margin:

Surgical Intervention and Margin Status
                  │
      ┌───────────┼───────────┐
      ▼           ▼           ▼
No Surgery /   Resection   Complete
Unresected     with Clean  Amputation
Necrotic Bone   Margins    (Clean Margin)
      │           │           │
      ▼           ▼           ▼
   6 WEEKS     2-3 WEEKS   2-5 DAYS

1. Unresected Necrotic Bone, Chronic Osteomyelitis, or No Surgery: 6 weeks of targeted parenteral or high-bioavailability oral therapy. In patients who are not surgical candidates, chronic oral suppressive therapy may be required.
2. Radical Surgical Debridement with Clean, Negative Bone Margins: 2 to 3 weeks of targeted antimicrobial therapy.
3. Complete Surgical Amputation (All infected bone removed, proximal margin histologically clean): 2 to 5 days (or until surgical wound closure/soft-tissue healing is complete).

The Landmark OVIVA Trial: Oral Step-Down Non-Inferiority

Historically, osteomyelitis treatment dogma mandated 6 weeks of continuous outpatient parenteral antimicrobial therapy (OPAT) via central vascular access. The paradigm shifted with the publication of the OVIVA (Oral Versus Intravenous Antibiotics for Bone and Joint Infection) trial (Li et al., New England Journal of Medicine, 2019).

• Study Design: Multicenter, randomized, open-label non-inferiority trial across 26 UK hospitals enrolling 1,054 patients with complex bone and joint infections (including osteomyelitis, native joint septic arthritis, and prosthetic joint infections). Patients were randomized within 7 days of surgical intervention or diagnosis to receive either continuous IV therapy or early oral antimicrobial therapy for a total duration of 6 weeks.
• Primary Endpoint: Definite treatment failure at 1 year post-randomization.
• Key Results:
  • Treatment failure occurred in 14.6% of the intravenous group versus 13.2% of the oral group (risk difference: -1.4%, 95% CI: -5.6% to 2.9%), easily fulfilling the prespecified non-inferiority margin of 5%.
  • Vascular line-related complications (central line infections, venous thrombosis, line occlusion) were significantly higher in the IV cohort (14.6% vs. 1.0%, $p < 0.001$).
  • Hospital length of stay was significantly shorter in the oral cohort (median 6 days vs. 9 days).
• Clinical Pharmacotherapy Application: Patients with bone and joint infections who are clinically stable, have an identified pathogen with confirmed in vitro susceptibility, and possess preserved gastrointestinal absorption can be safely transitioned to high-bioavailability oral antimicrobials (such as fluoroquinolones, linezolid, trimethoprim-sulfamethoxazole, clindamycin, or high-dose beta-lactams). This strategy avoids central venous catheter morbidity, reduces hospital stay, and dramatically lowers healthcare expenditures without compromising clinical cure.

---

Native Joint Septic Arthritis

Septic arthritis of a native synovial joint is an acute orthopedic emergency. Bacterial proliferation within the closed, vascular synovial space generates rapid chondrocyte death and irreversible articular cartilage loss within 24 to 48 hours due to bacterial toxins and host neutrophilic proteases.

Clinical Presentation and Synovial Fluid Differential

Manifests with acute joint pain, joint effusion, warmth, erythema, and marked restriction of passive and active range of motion. The knee is involved in $>50\%$ of cases, followed by hip, shoulder, wrist, and ankle.

Microbiology and Targeted Management

1. Staphylococcus aureus (MSSA and MRSA): Most common etiology across all age groups (>50% of adult cases). Treated with Cefazolin (2 g IV q8h) or Nafcillin (2 g IV q4h) for MSSA, or Vancomycin (AUC 400–600) or Daptomycin (6–8 mg/kg/day) for MRSA.
2. Streptococcus Species (S. pyogenes, S. agalactiae, S. pneumoniae): Treated with Ceftriaxone (2 g IV daily) or Penicillin G.
3. Neisseria gonorrhoeae (Disseminated Gonococcal Infection - DGI): Predominant pathogen in young, sexually active, healthy adults. Classically presents with the triad of tenosynovitis, dermatitis (painless, necrotic pustules on distal extremities), and migratory polyarthralgia, which subsequently settles into a purulent monoarthritis. Treated with Ceftriaxone 1 to 2 g IV daily for 7 to 14 days.
4. Gram-Negative Bacilli: Associated with intravenous drug use, advanced age, and immunosuppression. Treated with Ceftriaxone, Cefepime, or a fluoroquinolone for 3 to 4 weeks.

Source Control and Antimicrobial Duration

• Urgent Joint Decompression: Antimicrobial therapy is ineffective without mechanical joint drainage. Drainage is accomplished via serial needle arthrocentesis, arthroscopic lavage and debridement, or open arthrotomy (indicated for hip or shoulder joints, loculated effusions, or failure of needle aspiration).
• Duration of Therapy: Typically 2 to 4 weeks total. Uncomplicated gonococcal or streptococcal arthritis may be treated for 7 to 14 days; S. aureus and Gram-negative bacilli require 3 to 4 weeks of therapy.

---

Prosthetic Joint Infection (PJI)

Prosthetic joint infection occurs in 1% to 2% of primary arthroplasties and up to 5% of revision surgeries. Managing PJI requires multidisciplinary coordination between orthopedic surgeons and infectious diseases pharmacists.

Diagnostic Criteria (MSIS / 2018 International Consensus Meeting)

Diagnosis requires either 1 Major Criterion or scoring $\ge 6$ points across Minor Criteria:

• Major Criteria:
  1. A sinus tract communicating with the prosthetic joint.
  2. Two positive periprosthetic cultures yielding phenotypically identical microorganisms.
• Minor Criteria: Elevated serum CRP ($>10\text{ mg/L}$) and ESR ($>30\text{ mm/h}$); elevated synovial WBC ($>3,000\text{ cells/mcL}$ in chronic, $>10,000\text{ cells/mcL}$ in acute) and PMN percentage ($>70\%$ to $80\%$); positive synovial leukocyte esterase or alpha-defensin immunoassay; single positive tissue culture.

Surgical Strategies in PJI

                                PJI SURGICAL STRATEGY
                                          │
             ┌────────────────────────────┼────────────────────────────┐
             ▼                            ▼                            ▼
     DAIR STRATEGY                TWO-STAGE EXCHANGE            ONE-STAGE EXCHANGE
  - Symptoms < 3 weeks         - Gold standard in US         - Complete explantation
  - Implantation < 30 days     - Resistant pathogens (MRSA,    and immediate
  - Well-fixed prosthesis        Pseudomonas, fungi)           reimplantation
  - Retain implant; exchange   - Stage 1: Explant + spacer   - Highly selected cases
    modular components         - Stage 2: Reimplant 6-12 wk    (known susceptible organism,
  - Biofilm-active therapy       after antibiotic course       good bone stock)

1. Debridement, Antibiotics, and Implant Retention (DAIR):
   • Eligibility: Acute onset of symptoms ($<3\text{ weeks}$) OR early postoperative infection occurring $<30\text{ days}$ after arthroplasty; stable, well-fixed prosthesis with no radiographic loosening; intact soft-tissue envelope; and pathogen susceptible to oral biofilm-active agents.
   • Surgical Mandate: Radical synovectomy with mandatory exchange of modular components (polyethylene liner and modular femoral head). Exchanging modular parts permits physical debridement of biofilm on the back of the liner and inspects the bone-implant interface.
2. Two-Stage Exchange Arthroplasty:
   • Gold Standard in North America for chronic PJI, loose implants, sinus tracts, or difficult-to-treat organisms (MRSA, fluoroquinolone-resistant Pseudomonas, VRE, and fungal PJI).
   • Stage 1: Complete hardware removal, aggressive debridement, and placement of an articulating or static antibiotic-loaded bone cement (ALBC) spacer (polymethylmethacrylate [PMMA] loaded with vancomycin, tobramycin, or gentamicin).
   • Antimicrobial Course: 4 to 6 weeks of pathogen-directed systemic therapy, followed by an antibiotic-free holiday of 2 to 4 weeks. During this holiday, clinical signs, ESR/CRP, and synovial fluid re-aspiration are evaluated to confirm infection eradication.
   • Stage 2: Reimplantation of permanent revision prosthesis.
3. One-Stage (Single-Stage) Exchange: Removal of the infected prosthesis, debridement, and immediate reimplantation of a new cemented prosthesis in a single surgical procedure. Widely utilized in select European centers for patients with good bone stock, intact soft tissues, and known susceptible organisms.

---

Biofilm Dynamics and Rifampin Combination Therapy

Staphylococcal Biofilm Biology

When staphylococci (S. aureus, S. epidermidis) contact metallic or polymer surfaces (titanium, cobalt-chromium, polyethylene), they adhere via hydrophobic interactions and MSCRAMMs. Within hours, bacteria proliferate and secrete an extracellular polymeric substance (EPS) matrix composed of polysaccharide intercellular adhesin (PIA), extracellular DNA (eDNA), and proteins.

As the biofilm matures, interior bacteria enter a stationary, metabolically quiescent state known as persister cells. Because cell-wall active antimicrobials (beta-lactams, vancomycin) require active peptidoglycan synthesis and cell replication, they exhibit minimal bactericidal activity against sessile biofilm bacteria, with minimum biofilm eradication concentrations (MBEC) exceeding standard MICs by $100\times$ to $1,000\times$.

Rifampin: Mechanism and Biofilm Sterilization

Rifampin binds to the $\beta$-subunit of bacterial DNA-dependent RNA polymerase (rpoB), blocking RNA transcription. Because of its lipophilic character, rifampin penetrates the dense EPS biofilm matrix and kills slow-growing, stationary-phase staphylococci. In the landmark randomized trial by Zimmerli and colleagues (JAMA 1998), rifampin-containing combination therapy achieved a 100% cure rate in orthopedic foreign-body infections managed with implant retention, compared to 58% in regimens without rifampin.

Rifampin Combination Regimen in DAIR

1. Initial Intravenous Phase:
   • MSSA: Cefazolin 2 g IV q8h (or Nafcillin 2 g IV q4h) PLUS Rifampin 300 to 450 mg PO BID.
   • MRSA: Vancomycin IV (AUC 400–600) OR Daptomycin 6–8 mg/kg IV daily PLUS Rifampin 300 to 450 mg PO BID.
2. Oral Step-Down Partner Phase:
   • Combine Rifampin with a highly bioavailable companion agent:
     • First Line: Ciprofloxacin 750 mg PO BID OR Levofloxacin 750 mg PO daily (if fluoroquinolone-susceptible). Fluoroquinolones exhibit bone penetration and documented bactericidal synergy with rifampin.
     • Second Line (Fluoroquinolone-resistant or intolerant): Trimethoprim-Sulfamethoxazole 1 DS tablet PO BID; OR Doxycycline 100 mg PO BID; OR Minocycline 100 mg PO BID.
3. Total Duration of Rifampin Regimen in DAIR:
   • Total Hip Arthroplasty (THA) or Total Shoulder Arthroplasty (TSA): 3 months total.
   • Total Knee Arthroplasty (TKA): 6 months total (extended duration due to limited regional soft-tissue coverage, tenuous microvasculature, and higher historical failure rates).

Critical Clinical Rules for Rifampin Use

Pharmacokinetics, Drug Interactions, and Toxicology

• Potent Cytochrome P450 Induction: Rifampin is a potent inducer of hepatic CYP3A4, CYP2C9, CYP2C19, CYP1A2, and the P-glycoprotein (P-gp) efflux transporter.
  • Direct Oral Anticoagulants (DOACs): Co-administration with apixaban, rivaroxaban, or dabigatran decreases DOAC area-under-the-curve by $>50\%$, leading to therapeutic failure and stroke/venous thromboembolism. DOACs are contraindicated; switch to low-molecular-weight heparin or warfarin (with intensive INR monitoring and anticipated 2- to 3-fold warfarin dose increases).
  • Immunosuppressants: Dramatically lowers concentrations of tacrolimus, cyclosporine, and mTOR inhibitors, risking allograft rejection in transplant recipients.
  • Azole Antifungals, Opioids, Oral Contraceptives: Significant decreases in drug exposure; patients require alternative contraceptive methods.
• Adverse Effects and Monitoring:
  • Hepatotoxicity: Transient transaminitis occurs in up to 20% of patients; severe drug-induced liver injury requires monitoring baseline and biweekly AST, ALT, and bilirubin.
  • Bodily Fluid Discoloration: Benign orange-red discoloration of urine, tears, sweat, and saliva. Counsel patients that soft contact lenses will be permanently stained.
  • Hypersensitivity: Drug-induced fever, eosinophilia, thrombocytopenia, and a "flu-like" syndrome (more common with intermittent high-dose administration).